Bruker is a world-leading high-tech company in the field of analytical measurement systems and software solutions. For more than 60 years, Bruker’s high-performance scientific instruments and analytical and diagnostic solutions have enabled scientists to study substances and living organisms at molecular, cellular and microscopic levels. Working closely with partners and customers, Bruker drives innovation, productivity and customer success in molecular research in the areas of life sciences, pharmaceutical applications, microscopy, nanoanalytics and industrial applications. Today, more than 8,500 employees work at Bruker at over 90 locations on all continents.

As part of the project “TherSys”, Bruker is working with their cooperation partners on a novel theranostic system. Theranostic systems that combine therapy and diagnostics are still being developed before being translated into the clinic. They promise increases in precision and thus effectiveness in the treatment of diseases such as cancer. The aim is to develop novel theranostic strategies in which universally applicable RNA drug carrier systems with extended functionalities for real-time tracking and localized therapeutic intervention are used. For this purpose, RNA active ingredients will be combined with magnetic nanoparticulate systems. The aim of Bruker’s subproject is to set up and research the instrumentation necessary for theranostic intervention for the first time. This innovative project underlines Bruker’s motto “Improving Life Through Inspiring Science” by showing how, in collaboration with partners, the limits of what is currently possible can be pushed and completely new approaches can be evaluated and developed.

For Bruker, the TherSys project represents a great opportunity to develop and advance novel theranostic strategies with financial support from the German government and in close exchange with high-level cooperation partners